Stefano Cascinu
#135,525
Most Influential Person Now
Researcher
Stefano Cascinu's AcademicInfluence.com Rankings
Stefano Cascinumedical Degrees
Medical
#2344
World Rank
#2763
Historical Rank
Oncology
#137
World Rank
#142
Historical Rank
Stefano Cascinuphilosophy Degrees
Philosophy
#6813
World Rank
#9916
Historical Rank
Logic
#3919
World Rank
#5149
Historical Rank
Download Badge
Medical Philosophy
Stefano Cascinu's Degrees
- PhD Medical Oncology University of Bologna
- Doctorate Medicine University of Bologna
Why Is Stefano Cascinu Influential?
(Suggest an Edit or Addition)Stefano Cascinu's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. (2011) (1721)
- PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. (2009) (425)
- Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. (2002) (384)
- Addressing the challenges of pancreatic cancer: future directions for improving outcomes. (2015) (383)
- Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). (2000) (376)
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. (2014) (375)
- Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. (2009) (326)
- Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. (2007) (318)
- Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial (2007) (305)
- Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). (2007) (287)
- Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. (2004) (257)
- Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. (2000) (218)
- Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. (1994) (189)
- The evolving role of microsatellite instability in colorectal cancer: A review. (2016) (180)
- Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (162)
- PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. (2015) (157)
- Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis (2016) (144)
- Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. (2006) (142)
- Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) (2009) (140)
- Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy (2009) (139)
- Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? (2003) (138)
- Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. (1995) (138)
- Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. (1999) (135)
- Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. (2007) (134)
- Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. (2008) (134)
- Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. (2012) (133)
- Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. (2007) (132)
- Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? (2012) (130)
- Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. (1994) (127)
- Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. (2016) (126)
- Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. (2008) (122)
- VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study (2014) (111)
- Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma (2013) (107)
- Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients (2015) (105)
- Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. (2018) (103)
- Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer (2002) (103)
- Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. (2008) (102)
- Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer (2004) (102)
- Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients (2012) (102)
- Phase II study of paclitaxel in pretreated advanced gastric cancer (1998) (101)
- Role of maspin in cancer (2013) (100)
- Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study (2009) (96)
- Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. (1993) (95)
- Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. (1997) (94)
- Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. (2012) (92)
- Real-world study of everolimus in advanced progressive neuroendocrine tumors. (2014) (91)
- A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. (2000) (90)
- Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. (2018) (89)
- A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) (1999) (88)
- Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? (2016) (88)
- The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management (2014) (84)
- Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy (2007) (83)
- Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. (2014) (83)
- Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. (2018) (81)
- Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. (2004) (80)
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. (2022) (79)
- High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer (2015) (77)
- Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis (2009) (77)
- Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. (2013) (77)
- BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies (2015) (77)
- Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. (2005) (75)
- VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib (2012) (75)
- Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma (2013) (74)
- Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. (2008) (74)
- Insulin‐like growth factor 1 expression correlates with clinical outcome in K‐RAS wild type colorectal cancer patients treated with cetuximab and irinotecan (2010) (73)
- Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never‐Smokers and EGFR‐Mutant Patients (2018) (71)
- High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) (2004) (71)
- BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights (2019) (71)
- Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. (2017) (70)
- Bioresorbable Airway Splint Created with a Three-Dimensional Printer (2013) (70)
- MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? (2015) (70)
- Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. (2007) (70)
- Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? (2015) (69)
- FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study (2012) (69)
- Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients (2011) (69)
- A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. (1995) (69)
- Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors (2014) (68)
- Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. (2020) (67)
- Metabolic alterations in renal cell carcinoma. (2015) (67)
- Prognostic Role of Thymidylate Synthase Polymorphisms in Gastric Cancer Patients Treated with Surgery and Adjuvant Chemotherapy (2005) (66)
- Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR‐TKIs and mTOR inhibitor (2014) (65)
- State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. (2013) (65)
- Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations (2014) (64)
- Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells (2013) (64)
- Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue (2016) (64)
- Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. (2010) (63)
- The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. (2007) (62)
- Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy (2016) (62)
- The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment (2014) (61)
- Gastric cancer: Translating novels concepts into clinical practice. (2019) (61)
- Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach (2013) (59)
- Inhibition of Vascular Endothelial Growth Factor by Octreotide in Colorectal Cancer Patients (2001) (58)
- The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). (2014) (58)
- Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. (2005) (57)
- Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. (2004) (57)
- Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). (2008) (56)
- Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. (2015) (56)
- The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. (2011) (55)
- Mucinous Rectal Adenocarcinoma Can Be Associated to Tumor Downstaging after Preoperative Chemoradiotherapy (2007) (55)
- Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. (2014) (55)
- Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). (2002) (55)
- Association of thymidylate synthase polymorphisms with gastric cancer susceptibility (2004) (54)
- Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder (2012) (54)
- Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going (2018) (54)
- Essential role of Gli proteins in glioblastoma multiforme. (2013) (54)
- A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer (2012) (54)
- Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey (2014) (54)
- Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. (2016) (54)
- HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. (2002) (54)
- Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib (2015) (54)
- Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. (2011) (53)
- 5-Fluorouracil pharmacogenomics: still rocking after all these years? (2011) (53)
- Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. (2014) (53)
- Hyponatremia in cancer patients: Time for a new approach. (2016) (53)
- An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation (2002) (52)
- Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. (2015) (52)
- A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (1999) (52)
- The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management (2012) (52)
- Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New (2016) (52)
- Role of STAT3 pathway in genitourinary tumors (2015) (52)
- Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. (2002) (51)
- Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. (2014) (51)
- Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. (2001) (50)
- Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. (1996) (49)
- Chemotherapy for advanced gastric cancer: across the years for a standard of care (2007) (49)
- Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients (2015) (49)
- Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options (2007) (49)
- Advanced Digestive Neuroendocrine Tumors: Metastatic Pattern Is an Independent Factor Affecting Clinical Outcome (2014) (49)
- Treatment‐related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up‐to‐date review and meta‐analysis of clinical trials (2015) (49)
- Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization (2019) (48)
- Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer (2019) (48)
- CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors (2014) (47)
- Resection-line involvement in gastric cancer patients undergoing curative resections: implications for clinical management. (1999) (47)
- Pain and its treatment in hospitalized patients with metastatic cancer (2003) (47)
- Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients. (2017) (47)
- A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients (2017) (47)
- A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer (2001) (46)
- Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management (2015) (45)
- Patterns of recurrence of bronchioloalveolar cell carcinoma after surgical resection: a radiological, histological, and immunohistochemical study. (2003) (45)
- The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer (2015) (45)
- Performance at preoperative stair-climbing test is associated with prognosis after pulmonary resection in stage I non-small cell lung cancer. (2012) (44)
- Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer (2015) (44)
- A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. (2019) (44)
- Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. (2015) (44)
- Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. (2018) (44)
- Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients (2006) (44)
- Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy (2016) (43)
- Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer (2017) (43)
- Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta‐analysis of clinical trials (2014) (43)
- Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? (2012) (43)
- A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation (2007) (43)
- HER‐2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma (2003) (43)
- Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression (2014) (43)
- Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials (2016) (42)
- Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer (2015) (42)
- Stevens-Johnson syndrome during nivolumab treatment of NSCLC. (2018) (42)
- Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy (2015) (41)
- Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma (2013) (41)
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). (2019) (41)
- Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (1998) (41)
- Pancreatic cancer: progress in cancer therapy. (2008) (41)
- Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. (2014) (40)
- Tumor markers in the diagnosis of malignant serous effusions. (1997) (40)
- The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib (2015) (40)
- A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (2000) (39)
- Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis (2010) (39)
- Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. (2016) (39)
- Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens (2019) (39)
- Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. (2003) (39)
- Immunocytochemical evaluation of HER‐2/neu on fine‐needle aspirates from primary breast carcinomas (2003) (39)
- Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy (2016) (38)
- BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival. (2017) (38)
- Novel therapeutic approaches to cancer patients with bone metastasis. (2001) (38)
- Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target. (2015) (38)
- The prognostic nutritional index predicts survival and response to first‐line chemotherapy in advanced biliary cancer (2019) (38)
- Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis (2021) (38)
- Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma (1998) (37)
- Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? (2017) (36)
- Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. (2005) (35)
- Digestive and Liver Disease (2011) (35)
- Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. (2006) (35)
- The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey (2014) (35)
- Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment (2008) (35)
- 5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study. (1993) (35)
- Effects of Calcium and Vitamin Supplementation on Colon Cell Proliferation in Colorectal Cancer (2000) (35)
- COX-2 and NF-KB Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin (2007) (35)
- Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma (2015) (35)
- Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial (2006) (34)
- Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors (2004) (34)
- Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. (2012) (34)
- Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (2003) (34)
- Different doses of pamidronate in patients with painful osteolytic bone metastases (1998) (33)
- Pancreatic cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (33)
- Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients (2013) (33)
- Control of Chemotherapy-Induced Diarrhea with Octreotide (1994) (33)
- Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases (2013) (33)
- Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. (2013) (33)
- Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. (2012) (33)
- The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib (2020) (33)
- Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. (1997) (32)
- New target therapies in advanced pancreatic cancer. (2006) (32)
- Bevacizumab, bleeding, thrombosis, and warfarin. Author's reply (2003) (32)
- Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. (2003) (31)
- Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review. (2016) (31)
- GD2 expression in breast cancer (2017) (31)
- Locally advanced rectal cancer: the importance of a multidisciplinary approach. (2014) (31)
- Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study. (1999) (31)
- High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients (2000) (31)
- Genitourinary tumors, non-prostate (2012) (31)
- eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study (2016) (31)
- Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. (2014) (30)
- Gastric cancer treatment: a systematic review. (2004) (30)
- Chemotherapy for advanced pancreatic cancer: it may no longer be ignored. (1999) (30)
- Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study (2017) (29)
- Multimodal treatment of resectable pancreatic ductal adenocarcinoma. (2017) (29)
- A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. (1997) (29)
- Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma (2015) (29)
- Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis (2015) (29)
- The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation (2016) (29)
- Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey (2021) (29)
- The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer (2018) (28)
- Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality. (2019) (28)
- Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. (2015) (28)
- Cancer of pancreas. (2004) (28)
- Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside (2014) (28)
- Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells (2015) (27)
- Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis (2018) (27)
- Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience (2019) (27)
- Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex (2016) (27)
- High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A ‘GISCAD’ phase III study (1997) (26)
- Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab (2012) (26)
- Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal? (2015) (26)
- Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. (2013) (26)
- Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients (2015) (26)
- The Combination of Gemcitabine and Vinorelbine is an Active Regimen as Second-Line Therapy in Patients with Metastatic Breast Cancer Pretreated with Taxanes and/or Anthracyclines: a Phase I–II Study (2003) (26)
- Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia. (1995) (26)
- KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. (2007) (26)
- Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group (2016) (26)
- Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. (2006) (25)
- Lenvatinib as a therapy for unresectable hepatocellular carcinoma (2018) (25)
- Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID‐19 Outbreak (2020) (25)
- Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. (1993) (25)
- A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients (2019) (25)
- Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. (2006) (25)
- Early Detection of Recurrences in the Follow-up of Primary Breast Cancer in an Asymptomatic or Symptomatic Phase (2004) (25)
- Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of (2017) (25)
- Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research. (1997) (25)
- Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials (2019) (25)
- Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma (2016) (25)
- Nerve Growth Factor Receptor Immunoreactivity in Breast Cancer Patients (2001) (25)
- Neuroprotectant drugs in cisplatin neurotoxicity. (1996) (24)
- Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. (2009) (24)
- Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? (2017) (24)
- Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma (2017) (24)
- Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. (2010) (24)
- Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. (1992) (24)
- Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. (2020) (23)
- Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity. (2012) (23)
- Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC) (2016) (23)
- Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. (2000) (23)
- Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) (2019) (23)
- Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer (2013) (23)
- Ipsilateral supraclavicular lymph nodes metastases from breast cancer as only site of disseminated disease. Chemotherapy alone vs. induction chemotherapy to radical radiation therapy. (2001) (23)
- ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib (2019) (23)
- A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer (2003) (23)
- An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. (2009) (23)
- Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study (2021) (22)
- Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer (2006) (22)
- Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus (2018) (22)
- Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients (1997) (22)
- Liver metastases from colorectal cancer. (1997) (22)
- Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. (2009) (21)
- Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin (2019) (21)
- Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. (2019) (21)
- Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy (2019) (20)
- Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. (2016) (20)
- Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy (2021) (20)
- A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. (2015) (20)
- Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. (2001) (20)
- New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. (2015) (20)
- The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy (2016) (20)
- Management of diarrhea induced by tumors or cancer therapy. (1995) (20)
- Chromium Exposure and Germinal Embryonal Carcinoma: First Two Cases and Review of the Literature (2015) (20)
- Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW (2018) (19)
- Cutaneous seeding after ultrasound‐guided percutaneous ethanol injection for treatment of hepatocellular carcinoma (2001) (19)
- VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. (2013) (19)
- Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. (2015) (19)
- S‐phase fraction can predict event free survival in patients with pT2‐T3N0M0 colorectal carcinoma (1998) (19)
- Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer (2001) (19)
- Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis (2017) (19)
- Survival in patients with clear cell renal cell carcinoma is predicted by HIF-1α expression. (2015) (18)
- Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS) (2015) (18)
- Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? (2010) (18)
- Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy (2004) (18)
- Emerging Immunotargets in Metastatic Renal Cell Carcinoma. (2016) (18)
- Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study) (2008) (18)
- Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer (2015) (18)
- O-0011FREQUENCY OF S492R MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR: ANALYSIS OF PLASMA DNA FROM METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH PANITUMUMAB OR CETUXIMAB MONOTHERAPY (2014) (18)
- The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab (2017) (18)
- Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. (1992) (18)
- The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy (2017) (18)
- Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). (2015) (18)
- Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care) (2017) (18)
- Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial (2011) (17)
- Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer (2010) (17)
- A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma (2008) (17)
- Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. (2015) (17)
- Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib (2021) (17)
- Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. (2016) (17)
- Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin. (1994) (17)
- Breast ultrasonography (BU) in the screening protocol for women at hereditary‐familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? (2018) (17)
- The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. (2019) (17)
- The clinical impact of teniposide in the treatment of elderly patients with small-cell lung cancer. (1997) (17)
- Cetuximab: still an option in the treatment of pancreatic cancer? (2013) (17)
- Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy (2010) (17)
- Experience with Intrapleural Natural Beta Interferon in the Treatment of Malignant Pleural Effusions (1991) (17)
- The route to personalized medicine in bladder cancer: where do we stand? (2015) (17)
- Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma (2013) (16)
- The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer. (2014) (16)
- Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History (2017) (16)
- Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. (2013) (16)
- Molecular Profile and Clinical Variables in Brca1-Positive Breast Cancers. A Population-Based Study (2005) (16)
- Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A “real-life” study. (2015) (16)
- Is there a role for chemotherapy after local relapse in high‐grade osteosarcoma? (2019) (16)
- Transient sunitinib resistance in gastrointestinal stromal tumors. (2013) (16)
- Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer : A low cost effective regimen (2002) (16)
- Maspin expression is a favorable prognostic factor in non-small cell lung cancer. (2012) (16)
- Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients (2018) (16)
- The Role of Levamisole in the Adjuvant Treatment of Stage III Colon Cancer Patients: A Randomized Trial of 5-Fluorouracil and Levamisole Versus 5-Fluorouracil Alone (2003) (16)
- Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. (2014) (16)
- Out-of-pocket costs for cancer survivors between 5 and 10 years from diagnosis: an Italian population-based study (2016) (15)
- S‐phase fraction and tumor aneuploidy in colorectal carcinoma of young patients (1996) (15)
- Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis (2022) (15)
- Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma (2016) (15)
- Vascular Endothelial Growth Factor and p53 Expressions in Liver and Abdominal Metastases from Colon Cancer (2003) (15)
- Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade? (2003) (15)
- Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy (2015) (15)
- Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients (2012) (15)
- Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. (2015) (15)
- Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. (2019) (15)
- Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey (2016) (15)
- Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy (2019) (15)
- Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study (2020) (14)
- Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study (2007) (14)
- Locoregional treatments of unresectable liver metastases from colorectal cancer. (1998) (14)
- Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand? (2015) (14)
- Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials. (2011) (14)
- Social Support Networks and Depression of Women Suffering from Early-Stage Breast Cancer: A Case Control Study (2009) (14)
- The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors (2015) (14)
- Combinations of the immunocytokine F16-IL2 with doxorubicin or with paclitaxel investigated in phase Ib studies in patients with advanced solid tumors. (2010) (14)
- Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients (2005) (14)
- Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol (2018) (13)
- Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. (2012) (13)
- Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. (2014) (13)
- State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. (2011) (13)
- Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies (2019) (13)
- Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. (2005) (13)
- Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature (2015) (13)
- Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison (2021) (13)
- Borderline resectable pancreatic cancer: More than an anatomical concept. (2017) (12)
- The Value of Oxaliplatin in Combination with Continuous infusion ± Bolus 5-Fluorouracil and Levo-Folinic Acid in Metastatic Colorectal Cancer Progressing after 5FU-Based Chemotherapy: A Giscad (Italian Group for the Study of Digestive Tract) Cancer Phase II Trial (2000) (12)
- The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis (2020) (12)
- Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review (2017) (12)
- Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib (2020) (12)
- Drug therapy in diarrheal diseases in oncology/hematology patients. (1995) (12)
- Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. (2011) (12)
- A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors. (2013) (11)
- Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. (2012) (11)
- Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. (2021) (11)
- Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials (2013) (11)
- The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. (2019) (11)
- Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis (2015) (11)
- Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? (2016) (11)
- Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review. (2009) (11)
- Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma (2016) (11)
- HER family Receptor Expression and Prognosis in Pancreatic Cancer (2015) (11)
- Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity (2017) (11)
- Adverse events as potential predictive factors of activity in advanced hepatocellular carcinoma patients treated with lenvatinib. (2021) (11)
- Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer. (2015) (11)
- Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants. (2021) (11)
- Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. (2020) (11)
- Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. (2015) (11)
- [11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas (2014) (11)
- Resected biliary tract cancers: a novel clinical-pathological score correlates with global outcome. (2013) (11)
- First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial (2017) (11)
- Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. (2022) (11)
- Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer. (1994) (11)
- Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1α—Final results of the ALICE-2 study. (2016) (11)
- Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study (2020) (11)
- Immunohistochemical telomeric-repeat binding factor-1 expression in gastrointestinal tumors. (2000) (11)
- Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. (2019) (11)
- Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1 (2009) (11)
- Clinical and Pathologic Predictors of Clinical Outcome of Malignant Pleural Mesothelioma (2016) (10)
- Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma (2021) (10)
- Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients. (2002) (10)
- [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]. (2015) (10)
- Gemcitabine (GEM) and 5-fluorouracil (5 FU) in advanced pancreatic cancer: A GISCAD phase II study (1997) (10)
- Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis (2015) (10)
- 6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial (2009) (10)
- Cytokinetic effects of interferon in colorectal cancer tumors: implications in the design of the interferon/5-fluorouracil combinations. (1993) (10)
- Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. (2016) (10)
- Lgr5 expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses. (2015) (10)
- Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results. (2006) (10)
- KIT and PDGFR a mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study (2008) (9)
- Emerging Immunotargets in Bladder Cancer. (2016) (9)
- Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis (2021) (9)
- Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy (2001) (9)
- Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (2020) (9)
- Chemotherapy for Advanced Pancreatic Cancer: The History is Changing (1998) (9)
- Immunotherapy in the treatment of colorectal cancer: a new kid on the block (2018) (9)
- Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report (2016) (9)
- Altering macrophage polarization in the tumor environment: the role of response gene to complement 32 (2014) (9)
- Treatment of metastatic colorectal cancer with monoclonal antibody to vascular endothelial growth factor: does the metastatic site make the difference? (2003) (9)
- Feasibility of preoperative chemoradiation in rectal cancer patients aged 70 and older. (2005) (9)
- Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach (2020) (9)
- An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study (2018) (9)
- The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker? (2015) (9)
- Phase II Trial of Panitumumab in Combination with Oxaliplatin and Capecitabine Chemotherapy as 1st Line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases: The Metapan Study (2012) (9)
- Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. (2013) (9)
- Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (2016) (9)
- Gastrointestinal Cancer Refractory to Chemotherapy: A Role for Octreotide? (2001) (9)
- Effective prevention of 5-fluorouracil-induced superficial phlebitis by ketoprofen lysine salt gel. (2003) (9)
- A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. (1996) (9)
- The role of immune checkpoint inhibitors in the treatment sequence of advanced Gastric or Gastro-esophageal Junction cancer: a Systematic Review and Meta-analysis of randomized trials. (2022) (9)
- Prognostic Factors in Pancreatic Cancer: The Role of Perineural, Vascular and Lymphatic Invasion and of Ca19-9 (2013) (9)
- The generally low sensitivity of CA 125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype. (2020) (8)
- Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey (2021) (8)
- Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status (2019) (8)
- Pretreatment neutrophil to lymphocyte ratio may be an useful tool in predicting survival in early triple-negative breast cancer patients. (2014) (8)
- Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study (2022) (8)
- Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming? (2013) (8)
- Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan. (2009) (8)
- The Tower of Babel of liver metastases from colorectal cancer: are we ready for one language? (2013) (8)
- Chemo-embolization in the treatment of liver metastases from colorectal cancer. (1996) (8)
- Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. (2012) (8)
- Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial. (2009) (8)
- Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice (2021) (8)
- Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients. (2014) (8)
- ROLE OF STEREOTACTIC RADIOSURGERY FOR THE TREATMENT OF BRAIN METASTASIS IN THE ERA OF IMMUNOTHERAPY: A SYSTEMATIC REVIEW ON CURRENT EVIDENCES AND PREDICTING FACTORS. (2021) (8)
- Present and future of personalized medicine in adult genitourinary tumors. (2015) (8)
- 1320PUse of nivolumab in elderly patients with advanced non-squamous NSCLC: Results from the Italian expanded access program (EAP) (2017) (8)
- Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy (2020) (8)
- Selecting the best treatment for an individual patient. (2012) (8)
- Carboplatin associated anemia treated with subcutaneous erythropoietin - a pilot-study. (1994) (8)
- The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD (2007) (8)
- The Italian Rare Pancreatic Exocrine Cancer Initiative (2019) (7)
- F31Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus (2016) (7)
- Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey (2014) (7)
- Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) (1999) (7)
- Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2 (2009) (7)
- The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference (2020) (7)
- High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer. (2019) (7)
- SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy. (2021) (7)
- Emerging antibodies for the treatment of pancreatic cancer (2017) (7)
- Are we ready to describe response or progression to immunotherapy in lung cancer? (2019) (7)
- Biological parameters on computed tomography guided fine needle aspiration biopsy from peripheral primary non-small cell lung cancer. (2002) (7)
- From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy (2020) (7)
- Male mammary myofibroblastoma: Two case reports and brief review of literature (2020) (7)
- Patient and Caregiver Needs in Oncology. An Italian Survey (2015) (7)
- Lenvatinib and pembrolizumab in advanced gastric cancer. (2020) (7)
- The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial (2020) (7)
- A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. (1999) (7)
- Temperament and character traits associated with health-related quality of life in cancer patients. (2012) (7)
- Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. (2013) (6)
- Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in Italy (2005) (6)
- Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in Italy (2005) (6)
- Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid (2017) (6)
- A Dose‐finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5‐Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E‐LARC Study) (2017) (6)
- Squamous cell carcinoma of the lung: clinical criteria for treatment strategy (2015) (6)
- Compliance with breast and cervical cancer screening programs in women: results from a population-based study. (2013) (6)
- Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study (2004) (6)
- The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation (2021) (6)
- Laparoscopic Surgery for Intrahepatic Cholangiocarcinoma: A Focus on Oncological Outcomes (2021) (6)
- Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial (2020) (6)
- Survival and quality of life in gastrointestinal tumors: two different end points? (2001) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis. (2019) (6)
- High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer. (1997) (6)
- Panitumumab for the treatment of metastatic colorectal cancer: a review. (2015) (6)
- Epidermal growth factor receptor status in stages of resected non-small cell lung cancer: implications for treatment with epidermal growth factor receptor inhibitors. (2011) (6)
- Erratum: Real-world study of everolimus in advanced progressive neuroendocrine tumors (The Oncologist, (2014) 19, (966-974), 10.1634/theoncologist.2014-0037) (2015) (6)
- To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer. (2018) (6)
- Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab (2015) (6)
- Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index (2021) (6)
- A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab. (2015) (6)
- Cholangiocarcinoma: new perspectives for new horizons (2021) (6)
- Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology (2015) (6)
- National survey of medical choices in caring for terminally ill patients in Italy, a cross-sectional study. (2010) (6)
- Intensive weekly chemotherapy for advanced gastric-cancer using 5-Fluorouracil, Cisplatin, epi-Doxorubicin, 6s-leucovorin and granulocyte-colony-stimulating factor. (1993) (6)
- Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib (2022) (6)
- Molecular biology for stage II colorectal cancer: the jury is still out. (2007) (6)
- Treating cancer with immunotherapy in HIV-positive patients: A challenging reality. (2019) (6)
- Intensive Weekly Chemotherapy for Elderly Gastric Cancer Patients, Using 5-Fluorouracil, Cisplatin, Epi-Doxorubicin, 6S-Leucovorin and Glutathione with the Support of G-CSF (1995) (6)
- Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer. (2006) (6)
- The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. (2011) (6)
- Phase II trial of 13-cis retinoic acid plus interferon-alpha in advanced squamous cell carcinoma of head and neck, refractory to chemotherapy. (1996) (6)
- Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach (2021) (6)
- KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma. (2015) (6)
- Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-α2b and folinic acid. The “GISCAD” experience (1994) (6)
- Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. (2013) (5)
- The combination of gemcitabine and oxaliplatin (GEM-OXAL) is feasible in patients with poor prognosis advanced non-small cell lung cancer (NSCLC). Results of a phase II study (2001) (5)
- Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial. (2021) (5)
- Primary breast carcinoma: immunocytochemical and immunohistochemical evaluation of biological parameters. (2000) (5)
- Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series (2019) (5)
- Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome. (2009) (5)
- Real-world study of everolimus in advanced progressive neuroendocrine tumors. (2015) (5)
- Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. (2014) (5)
- Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice (2006) (5)
- Influence of 5-fluorouracil and folinic acid on interleukin-18 production in colorectal cancer patients. (2002) (5)
- Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment. (2015) (5)
- 5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study. (1991) (5)
- Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence (2020) (5)
- New findings on thymic epithelial tumors: Something is changing. (2015) (5)
- Compliance and Outcomes in Locally Advanced Head and Neck Cancer Patients Treated with Alternating Chemoradiotherapy in Clinical Practice (2003) (5)
- O-007Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study (2016) (5)
- Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review. (2007) (5)
- Chemotherapy use at the end of life: An analysis of the decision making process. (2004) (5)
- Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis (2021) (5)
- Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients (2021) (5)
- Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy (2019) (5)
- Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma (2010) (5)
- Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy (2005) (5)
- A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study. (2017) (4)
- Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer (2020) (4)
- The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients (2005) (4)
- Is there an optimal choice in refractory colorectal cancer? A network meta-analysis. (2019) (4)
- Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literature. (2003) (4)
- 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab) (2015) (4)
- A phase II study of neoadjuvant antiangiogenic therapy combined with capecitabine (C) and radiotherapy (RT) in patients (pts) with locally advanced rectal cancer (LARC) (2008) (4)
- Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). (2015) (4)
- A Pilot Clinical Trial of Postoperative Intensive Weekly Chemotherapy Using Cisplatin, Epi-Doxorubicin, 5-Fluorouracil, 6S-Leucovorin, Glutathione and Filgrastim in Patients with Resected Gastric Cancer (1998) (4)
- Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit? (2014) (4)
- Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer. (2016) (4)
- Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer (2015) (4)
- Sidedness influences prognosis in colon cancer patients receiving an adjuvant therapy. A GISCAD analysis from three randomized trials including 5234 patients. (2017) (4)
- Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer (1996) (4)
- Chemotherapy use at the end of life: An analysis of the decision making process (2004) (4)
- Gender differences and outcome of melanoma patients (2015) (4)
- Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort (2019) (4)
- The impact of gender and immune system determinants on long-term survival in biliary tract cancer (2019) (4)
- Prediction of Bene fi t from Checkpoint Inhibitors in Mismatch Repair De fi cient Metastatic Colorectal Cancer: Role of Tumor In fi ltrating Lymphocytes (2020) (4)
- Compliance with Breast and Cervical Cancer Screening Programs in Women: Results from a Population-Based Study (2013) (4)
- A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. (2012) (4)
- Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. (1992) (4)
- Docetaxel chemotherapy for pancreatic cancer: Do results support certainty? Italian Group for the Study of Gastrointestinal Tract Carcinomas. (2000) (4)
- Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. (2020) (4)
- Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis (2021) (4)
- Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response (2019) (4)
- Prognostic Factors in Early Stage Non-Small Cell Lung Cancer: TheImportance of Number of Resected Lymph Nodes and Vascular Invasion (2013) (4)
- Effect of metformin on clinical outcome in advanced HCC patients receiving sorafenib. (2015) (4)
- Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient (2018) (4)
- Evidence Based Medicine (EBM) and Evidence Based Radiology (EBR) in the follow-up of the patients after surgery for lung and colon-rectal carcinoma. (2005) (4)
- Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus (2020) (4)
- 1226 Ondansetron vs granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis (1995) (4)
- A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel (2013) (4)
- Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. (2021) (4)
- Gastric Metastases from Breast Cancer: A Case Report (1989) (4)
- Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: A randomised phase II trial (2008) (3)
- Prognostic value of S-phase fraction in T3N0M0 gastric cancer. Implications for adjuvant chemotherapy. (2000) (3)
- Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT. (2015) (3)
- Dabrafenib-trametinib combination in 'field-practice': an Italian experience. (2018) (3)
- Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment (2012) (3)
- Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial (2019) (3)
- Gastric cancer: toward a cisplatin-free disease? (2014) (3)
- Delphi initiative for early-onset colorectal cancer (DIRECt). International Management Guidelines. (2022) (3)
- Recombinant human erythropoietin in chemotherapy-associated anemia. (1995) (3)
- Using of Androgen Receptor Expression as a Novel Potential Biomarker in Predicting Survival of Women with Metastatic Triple Negative Breast Cancer (2014) (3)
- Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1. (2014) (3)
- Breast cancer developing after therapy for Hodgkin's disease. (1993) (3)
- GD 2 expression in breast cancer (2017) (3)
- Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. (2012) (3)
- A Pilot Clinical Trial of Postoperative Adjuvant Intraperitoneal Cisplatin, 5-Fluorouracil, 6S-Leucovorin and Interferon Alpha 2b in Patients with Resected Gastric Cancer (1993) (3)
- Multicenter phase II study of temozolomide therapy for brain metastases in patients with malignant melanoma, breast cancer, or non-small cell lung cancer: Final results (2008) (3)
- Paclitaxel and Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil for Patients With Stage IIIC Breast Cancer With Ten or More Involved Axillary Lymph Nodes (2006) (3)
- The clinical impact of FEM regimen (5-fluorouracil, 4-epidoxorubicin and mitomycin-C) in advanced gastric cancer patients. (1995) (3)
- The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. (2018) (3)
- Angiogenetic pathway as a therapeutic target in renal cell carcinoma. (2012) (3)
- Diet and Lifestyle Habits in Early-Onset Colorectal Cancer: A Pilot Case-Control Study (2022) (3)
- Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (2022) (3)
- Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib (2021) (3)
- A cost–benefit analysis of chemotherapy for gastric cancer (2004) (3)
- Tumor response and symptom palliation from RAINBOW, a phase 3 trial of ramucirumab plus paclitaxel in previously treated advanced gastric cancer. (2020) (3)
- Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC). (2013) (3)
- Medical Treatment of Colorectal Cancer in Elderly (>70 Years): Giscad Experience and Future Perspectives (2002) (3)
- Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib (2021) (3)
- The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan/cetuximab. (2011) (3)
- Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? (2017) (3)
- Occult breast cancer: the uncommon presentation of a common disease. (2019) (3)
- Angiosuppression and Chemotherapy: Strategies Aimed at Their Integration in Cancer Patients (1999) (3)
- Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target. (2009) (3)
- Different effects of sunitinib, sorafenib, and pazopanib on inducing cancer cell death: The role of autophagy. (2013) (3)
- Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease. (2018) (3)
- A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. (1996) (3)
- Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy (2021) (3)
- Pretreatment levels of serum lactate dehydrogenase (LDH) and clinical outcome in metastatic colorectal cancer patients receiving first-line chemotherapy and bevacizumab. (2012) (2)
- LDH serum levels as a predictive factor for global outcome in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. (2014) (2)
- Neuroprotective effect of glutathione (GSH) on oxaliplatin (L-OHP)-based chemotherapy in advanced colorectal cancer patients (pts): a randomized double-blind placebo-controlled trial (2001) (2)
- Prognostic significance of ki67, p53, TS and EGFR in advanced gastric and gastroesophageal junction cancer patients treated with cetuximab plus FOLFIRI (FOLCETUX study) (2007) (2)
- Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study. (2018) (2)
- Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. (2022) (2)
- Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. (2020) (2)
- Anti-EGFR therapy in oesophagogastric cancer: precise but not enough. (2018) (2)
- Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study. (2022) (2)
- [Treatment of pancreatic cancer. Actuality and perspective]. (2015) (2)
- Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study. (2023) (2)
- Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study. (2022) (2)
- Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. (2022) (2)
- Temperament and Character Traits Associated with Health-Related Quality of Life in Cancer Patients (2012) (2)
- Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis (2022) (2)
- Evolution of Surgical Treatment of Colorectal Liver Metastases in the Real World: Single Center Experience in 1212 Cases (2021) (2)
- Treatment of elderly advanced gastric cancer patients with 5-fluorouracil and leucovorin combination. (1992) (2)
- Oral Anticancer Therapy Project: Clinical utility of a specific home care nursing program. (2016) (2)
- Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients (2020) (2)
- Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. (2016) (2)
- Efficacy of nitrosourea-based chemotherapy in recurrent malignant glioma according to time to adjuvant temozolomide failure: A pooled analysis. (2011) (2)
- PP 22 Analysis of HER-3, insulin-growth factor-1 (IGF-1), nuclear factor k-B (NF-kB) and epidermal growth factor receptor (EGFR) gene copy number (GCN) in the prediction of clinical outcome for K-RAS wild type colorectal cancer patients receiving irinotecan–cetuximab (2011) (2)
- Diagnostic and therapeutic algorithm for colorectal peritoneal metastases. A consensus of the peritoneal surface malignancies onco-team of the Italian society of surgical oncology. (2020) (2)
- Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN) (2021) (2)
- Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) (1999) (2)
- Non-small cell lung cancer, early stage (2012) (2)
- Ca 19.9 as an early predictor of response to first- and second-line treatment in patients with pancreatic cancer (2008) (2)
- Maspin Staining and Its Use as Biomarker in Lung Cancer (2015) (2)
- Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? : [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 (2017) (2)
- Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward? (2015) (2)
- Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). (2016) (2)
- A Pilot Clinical Trial of Surgical Adjuvant Treatment with High-Dose 6S-Leucovorin/5-Fluorouracil and Radiation Therapy for High-Risk Rectal Carcinoma (1994) (2)
- Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. (2011) (2)
- High-risk radically resected gastric cancer patients do not benefit of an adjuvant cisplatin containing regimen (2005) (2)
- F25Multigene profiling in incidentally- and clinically detected prostate cancer (2015) (2)
- Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma. (1995) (2)
- What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities (2016) (2)
- 1318PItalian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients (2017) (2)
- Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients (2014) (2)
- Adjuvant chemotherapy in colon cancer: can we improve quality of care? (2013) (2)
- M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer (2016) (2)
- 2110 Efficacy outcomes by severity of skin toxicity from ASPECCT: Randomized phase 3 study of panitumumab (pmab) versus cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) (2015) (2)
- Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum] (2019) (2)
- Highlights from the ASCO Genitourinary Symposium 2014: focus on renal and prostate cancer (2014) (2)
- Second-line treatment in patients with FOLFIRINOX-refractory pancreatic adenocarcinoma (PDAC): Doublets or single-agent chemotherapy? (2014) (2)
- 3*A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab (2015) (2)
- Have enteric infections a role in 5-fluorouracil-associated diarrhea? (1995) (2)
- Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study. (2019) (2)
- A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer (PANDORA). (2020) (1)
- Perspectives from American Society of Clinical Oncology: translational and clinical research highlights in breast and colorectal cancers. (2014) (1)
- Immune in fl ammation indicators in anal cancer patients treated with concurrent chemoradiation : training and validation cohort with online calculator ( ARC : Anal Cancer Response Classi fi er (2019) (1)
- Locally advanced or metastatic pancreatic tumors: Molecular biology may help to know it and to select the optimal treatment. (2013) (1)
- Biochemical modulation of fluoropyrimidines: the "GISCAD" studies. GISCAD (Italian Group for the Study of Digestive Tract Cancer). (1993) (1)
- PD-5 IDH1 in intrahepatic cholangiocarcinoma: A comparative genomic analysis and clinical impact (2022) (1)
- Outcome and prognostic factors after resection of liver metastases in patients with colorectal cancer. (2017) (1)
- Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) (2008) (1)
- New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression (2023) (1)
- Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments (2022) (1)
- Different doses of granulocyte colony stimulating factor to support a weekly chemotherapeutic regimen in advanced gastric cancer: a randomized study (1996) (1)
- 690PCLINICAL IMPACT OF FOLFIRINOX DOSE/SCHEDULE MODIFICATIONS (MFOLFORINOX) AND ADDITIONAL SUPPORTIVE MEASURES IN THE MANAGEMENT OF PANCREATIC CANCER (PDAC) PATIENTS (PTS). (2014) (1)
- Biochemical Modulation of Fluoropyrimidines: the “Giscad” Studies (1993) (1)
- Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis (2021) (1)
- Sorafenib in patients with hepatocellular carcinoma: 10 years of real life. (2019) (1)
- Reply to O. Corli et al and M. Lucchesi et al. (2016) (1)
- F19BRCA mutations and IGF-R1 expression in modulating sensitivity to Trastuzumab in patients with HER2-positive breast cancer (2016) (1)
- Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment (2008) (1)
- Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs). (2015) (1)
- A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial (2022) (1)
- Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. (2019) (1)
- Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study (2019) (1)
- Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: An analysis of dose intensity (2011) (1)
- Translational challenges from the 2014 Gastrointestinal Cancers Symposium: toward a true tailored therapy through effective research. (2014) (1)
- An evaluation of potential neuroprotective effect of reduced-glutathione (GSH) on oxaliplatin (OXA) based chemotherapy in advanced colorectal cancer patients (1999) (1)
- Nuclear factor-kb (NF-KB)tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer patients treated with cetuximab-irinotecan therapy (2007) (1)
- 709PSINGLE-AGENT OR DOUBLETS AS SECOND-LINE CHEMOTHERAPY AFTER FOLFIRINOX IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER. (2014) (1)
- [Non-small cell lung carcinoma: pathology, biology and prognosis]. (2004) (1)
- Expression of stem cell markers in pancreatic ductal adenocarcinoma and clinical relevance. (2013) (1)
- Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC) (2004) (1)
- Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) (2008) (1)
- Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors? (2022) (1)
- The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT (2022) (1)
- Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery. (2021) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Anal cancer: from an orphan disease to a curable malignancy? (2017) (1)
- 735 L-Leucovorin (LLV) as a modulator of 5-days 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): High dose (HD) versus low dose (LD) (1995) (1)
- Effect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatment. (2013) (1)
- Pierson syndrome (2020) (1)
- The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer (2018) (1)
- Effect of sunitinib and pazopanib on necrosis and autophagic cell death in cancer cells: Role of cathepsin B. (2013) (1)
- Inside the 2015 ASCO Genitourinary Cancers Symposium. (2015) (1)
- Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? (2023) (1)
- Trifluridine tipiracil (TAS 102) in patients with stage IV pretreated colorectal neoplasm: an experience from Rimini City Hospital. (2017) (1)
- P-126 Clustering analysis identified three IDH1-mutated intrahepatic cholangiocarcinoma's clusters with prognostic significance (2022) (1)
- Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities? (2010) (1)
- New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols. (2005) (1)
- Hedgehog (Hh) Signaling is a Predictor of Clinical Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (1)
- The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab. (2017) (1)
- Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs). (2019) (1)
- Perioperative anemia as prognostic factor in patients undergoing resection for non-small cell lung cancer. (2004) (1)
- The role of sidedness, EGFR gene copy number (GCN) and EGFR promoter methylation in RAS/BRAF wild type (WT) colorectal cancer (CRC) patients receiving irinotecan/cetuximab. (2017) (1)
- Correlation among [h-3] thymidine, flow-cytometry and proliferating cell nuclear antigen indexes in colorectal tumors. (1994) (1)
- After Pulmonary Resection in Stage I Non-Small Cell Lung Cancer Performance at Preoperative Stair-Climbing Test Is Associated With Prognosis (2012) (1)
- Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. (2011) (1)
- Locally advanced rectal cancer: new findings in anticancer therapy (2013) (1)
- E04Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study (2015) (1)
- Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? (2015) (1)
- Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters. (2022) (1)
- Thymidylate synthase (TS) protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil (5FU) (1999) (1)
- A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study (2019) (1)
- Is surgery an option after downstaging of liver metastases from pancreatic cancer following primary chemotherapy (2015) (1)
- Second-line chemotherapy in advanced biliary tract cancer: Who may benefit? (2019) (1)
- Correlation of KRAS mutational state with the expression of the hedgehog pathway in patients with pancreatic ductal adenocarcinoma. (2014) (1)
- Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. (2016) (1)
- BRCA mutations and IGF-R1 expression in modulating sensitivity to trastuzumab in HER2-positive breast cancer (2016) (1)
- Clinical Impact of [11C]-Methionine Positron Emission Tomography on the Treatment of Primary and Recurrent Gliomas (2012) (1)
- Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (2022) (1)
- Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC). (2004) (1)
- Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: A randomized phase II trial. (2010) (1)
- L47Osteopontin (OPN) and interleukin-6 (IL-6) as predictive biomarkers in HCC receiving loco-regional treatment: preliminary results (2015) (1)
- 243 Preoperative chemotherapy plus concomitant radiotherapy in rectal cancer patients (pts): updated results of a phase II study (2003) (1)
- F-38 The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management (2012) (1)
- 710PCLINICAL OUTCOME OF ELDERLY (>70Y) ADVANCED PANCREATIC CANCER PATIENTS RECEIVING CHEMOTHERAPY. (2014) (1)
- National Survey of Medical Choices in Caring for Terminally ill Patients in Italy, a Cross-Sectional Study (2010) (1)
- Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. (2019) (1)
- P-CHOP: Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study (2003) (1)
- Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib. (2015) (1)
- Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. (2023) (1)
- Hepatic Artery Administration of Docetaxel in Liver Metastases from Breast Carcinoma: A Feasibility Study (2005) (1)
- Prognostic role of thymidylate synthase (TS) gene polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. (2005) (1)
- Does immunotherapy change the treatment paradigm in metastatic gastric cancer? (2022) (1)
- A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. (2012) (1)
- Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT. (2016) (1)
- 713PACTIVITY, EFFICACY AND SAFETY OF NAB-PACLITAXEL (NAB-P) AND GEMCITABINE (G) IN ADVANCED PANCREATIC CANCER (APDAC) ELDERLY PATIENTS. (2014) (1)
- Maintenance therapy for metastatic colorectal cancer. (2015) (1)
- 837PPOOR RISK METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS ARE NOT A HOMOGENEOUS GROUP: A NEW STRATIFICATING MODEL IN THE ERA OF TARGETED THERAPY. (2014) (1)
- The importance of obstetric(midwife) in breast cancer prevention andrecurrence. (2017) (1)
- Multicentric, randomised, phase III trial of 2 different adjuvant chemotherapy regimens plus 3 versus 12 months of trastuzumab in HER2 positive breast cancer patients (Short-HER trial, NCT00629278).. (2008) (1)
- KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma. (2014) (1)
- A28Endocrine therapy is not effective in BRCA2 mutated breast cancers even when they express hormonal receptors (2015) (1)
- Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? (2016) (1)
- Relationship of number of resected lymph nodes in early-stage non-small cell lung cancer (NSCLC) and survival. (2011) (1)
- The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management (2014) (0)
- Single-nucleotide polymorphisms (SNPs) associated with outcome: The first experience in thymic tumors. (2014) (0)
- PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) (2010) (0)
- CMAR_A_197349 3631..3642 (2019) (0)
- Corrigendum to "Gastric cancer: Translating novels concepts into clinical practice" [Cancer Treatm. Rev. 79C (2019) 101889]. (2019) (0)
- Early onset of hyperthension and serum electrolite changes as potential predictive factors of activity in advanced HCC treated with sorafeinb: Results from a retrospective analysis of HCC-AVR group (2016) (0)
- PET and Octreoscan in the neuroendocrine tumors (NET) (2007) (0)
- Gastric Cancer: therapeutic choices in advanced disease (2014) (0)
- Retrospective analysis of sorafenib as first or second target therapy in mRCC patients in Italian centers: An update. (2013) (0)
- PI3K/AKT/mTOR pathway and androgen receptor expression as potential therapeutic targets for triple-negative breast cancer. (2015) (0)
- Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab. (2016) (0)
- Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. (2018) (0)
- L33LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy (2015) (0)
- PO-0806: Prognostic value of eosinophil levels in oropharyngeal cancer: a retrospective multicentric study (2020) (0)
- [Metastatic colorectal cancer: adjournments from ESMO 2006]. (2006) (0)
- PO-1212 Outcome of adjuvant hypofractionated radiotherapy concomitant to chemotherapy in bile duct carcinoma (2021) (0)
- H40Bone metastases (BMs) in patients with advanced non-small cell lung cancer (NSCLC): do they always correlate with poor prognosis? (2015) (0)
- D09Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + Bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh) (2016) (0)
- Small bowel adenocarcinoma (SBA) is a rare and heterogeneous disease: results of a retrospective analysis. (2017) (0)
- [The DUR studies: colon cancer adjuvants]. (2004) (0)
- Corrections to "Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?" (2017) (0)
- Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. (2016) (0)
- Determination of biological parameters on fine-needle aspirates from non-small cell lung cancer. (2003) (0)
- EP-1457: GemOx with low-dose RT and SBRT for locally advanced pancreatic cancer: preliminary safety results (2018) (0)
- Prognostic value of incidental betablockers use in metastatic colorectal cancer patients receiving first-line treatment. (2013) (0)
- Somatostatin analogs: is one better than other? (2017) (0)
- Poseban članak Sadašnja i buduća uloga medikalnog onkologa u profesionalnom zbrinjavanju onkoloških pacijenata: stav Evropskog udruženja za medikalnu onkologiju (ESMO) (2014) (0)
- AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma (2019) (0)
- A new prognostic score for biliary tract cancer: a multicenter experience. (2019) (0)
- FRI-474-AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma (2019) (0)
- M19Hyponatremia in cancer patients (2015) (0)
- 67P Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (2022) (0)
- [Role of docetaxel in the treatment of gastric cancer]. (2001) (0)
- Correlation of activated AKT and MAPK expression in liver metastases with clinical outcome in colorectal cancer patients receiving irinotecan/cetuximab treatment. (2012) (0)
- Angiogenesis genotyping, LDH serum levels, and treatment efficacy for advanced hepatocellular carcinoma patients receiving sorafenib. (2014) (0)
- Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. (2016) (0)
- Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report (2016) (0)
- [Paraneoplastic syndromes: a review]. (2005) (0)
- 2603 Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs) (2015) (0)
- F48Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer (2016) (0)
- H06Advanced non-small cell lung cancer (NSCLC): the prognostic role of systemic Immune-Inflammation Index (SII) (2015) (0)
- PG 10.05 Selecting the best treatment for an individual patient (2012) (0)
- Role of evaluating tumor infiltrating lymphocytes, programmed death-ligand 1 and mismatch-repair proteins expression in malignant mesothelioma. (2018) (0)
- 827PRENAL METASTASES TO PANCREAS: DO NOT OPERATE ALL AND ALWAYS? (2014) (0)
- Abstract 3401: Impact of VEGF and VEGFR polymorphisms on neuroendocrine tumors of the gastro-entero-pancreatic system (GEPNETs) outcome (2016) (0)
- Methylenetetrahydrofolate reductase 677C/T gene (MTHFR 677C/T) polymorphism, gastric cancer risk and genomic DNA hypomethylation. A report from the Italian group for genetic research in gastric cancer (2005) (0)
- The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib. (2012) (0)
- Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin (2017) (0)
- A novel approach to manage skin toxicity caused by cetuximab and panitumumab. (2011) (0)
- The point of view of medical oncologists. (2014) (0)
- Bevacizumab (B) combined to chemotherapy for first-line treatment of elderly patients with advanced colorectal cancer (CRC): results from a large community-based Italian observational study. (2012) (0)
- PO-1214 Toxicity profile of adjuvant hypofractionated Image-Guided Radiotherapy in biliary tract carcinoma (2021) (0)
- The Imprecision of “Precision Medicine” in Pancreatic Adenocarcinoma (2020) (0)
- Quality of Life and Anxious-depressive Symptoms in Cancer Patients Undergoing Mindfulness-based Interventions: Feasibility and Preliminary Outcomes on Prospective Single-centre Case-control Study (MIND4ME St.) (2017) (0)
- Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma. (2023) (0)
- 531PNEUTROPHIL/LYMPHOCYTE RATIO AND PIASTRINOSIS CORRELATE WITH CLINICAL OUTCOME IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING REGORAFENIB. (2014) (0)
- Insulin-like growth factor-1 (IGF-1) correlates with clinical outcome in metastatic colorectal patients treated with irinotecan/cetuximab combination (2008) (0)
- SO-3 Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma (2022) (0)
- Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies (2012) (0)
- Correlation of distinctive angiogenetic profiles with clinical outcome for different treatment sequences in mRCC. (2014) (0)
- Hepatocellular carcinoma: The beginning of a long journey. (2009) (0)
- A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients (2017) (0)
- Biosimilars in oncology: characteristics and insights (2013) (0)
- Primary Resistance to First-Line Bevacizumab in Metastatic Colorectal Cancer: Implications on Prognosis (2012) (0)
- Intensive up-front treatment versus a sequential approach in advanced gastric cancer patients: Does first line matter? (2012) (0)
- Author reply (0)
- Downstaging of liver metastases from pancreatic cancer following primary chemotherapy: A new indication for surgery? (2016) (0)
- Locally advanced versus metastatic pancreatic cancer: two different diseases with two different treatment approaches? (2013) (0)
- EP-1487: The prognostic role of haemoglobin in patients undergoing concurrent chemo-radiation for anal cancer (2018) (0)
- Cancer Stem Cell Genetic Profile as Predictor of Relapse in Radically Resected Colorectal Cancer (2012) (0)
- S phase fraction and ploidy in normal and tumoral colonic mucosa (2000) (0)
- Oral escalating dose of cyclosporine-a combined with 4-epidoxorubicin in advanced colorectal-cancer - a phase-I study. (1995) (0)
- H11Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy (2015) (0)
- EP-1461: Immune inflammation indicators in anal cancer patients treated with concurrent chemo-radiation (2018) (0)
- A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: A GISCAD trial (2019) (0)
- 732PShould pancreatic cancer be included in BRCA1/2 testing criteria? (2017) (0)
- Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer (2019) (0)
- 1005 ORAL HER-3, IGF-1, NF K-B and EGFR Gene Copy Number in the Prediction of Clinical Outcome for Colorectal Cancer Patients Receiving Irinotecan-cetuximab (2011) (0)
- 695PDOES FIRST-LINE THERAPY AFFECT THE OUTCOME OF PATIENTS WITH PANCREATIC CANCER? (2014) (0)
- Erratum to: Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC) (2016) (0)
- 481PDSidedness influences prognosis in stage III but not in stage II colon cancer patients receiving an adjuvant therapy: A GISCAD analysis from three randomized trials including 5234 patients (2017) (0)
- Adjuvant Treatment After Surgical Resection (2012) (0)
- 17265 Healthcare-associatedhepatitisCvirusinfection (2014) (0)
- Nuclear factor-kB (NF-kB) predicts outcome in locally advanced rectal cancer patients receiving radio-chemotherapy (2008) (0)
- 821PVEGF AND VEGFRS POLYMORPHISMS ANALYSIS IN ADVANCED RENAL CELL CARCINOMA TISSUES: IS HETEROGENEITY EVER THE ANSWER? (2014) (0)
- [Gastric carcinoma: an evolutionary scenario.] (2017) (0)
- Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment (2008) (0)
- Characterization of mismatch repair deficiency in biliary tract cancer. (2019) (0)
- A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC) (2019) (0)
- Abstract P1-18-06: First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? (2019) (0)
- First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? (2018) (0)
- Nuclear factor-kB (NF-kB), p53, survivin, Ki-67, and Bcl-2 as prognostic factors in locally advanced rectal cancer patients receiving radiochemotherapy. (2009) (0)
- GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen. (2015) (0)
- Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients (2023) (0)
- Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma. (2014) (0)
- Evolving Concepts in the Treatment of Stage IV Gastric Cancer (2021) (0)
- Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series (2019) (0)
- Clinical Outcome of advanced Gastric Cancer (GC) Patients Receiving First-Line Chemotherapy According to Tumour Histology and Location (2012) (0)
- [353] ADHESION OF IN VITRO GENERATED DENDRITIC CELLS TO HUMAN HEPATIC ENDOTHELIUM UNDER CONDITIONS OF FLUID FLOW (2007) (0)
- Correlation of biliary stenting with clinical outcome in patients with advanced pancreatic cancer treated with chemotherapy. (2012) (0)
- 828PBONE METASTASES FROM RCC ARE NOT ALWAYS ASSOCIATED WITH A POOR PROGNOSIS. (2014) (0)
- Prognostic role of a novel clinical-nutritional index in pancreatic ductal adenocarcinoma: The Pancreatic Adenocarcinoma Nutritional-Clinical Index (PANCIN). (2023) (0)
- P0323 : LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy (2015) (0)
- Emergency Department Visits among Cancer Patients during SARS-CoV-2 Pandemic (2023) (0)
- 698PCOX-2 STATUS MODULATES THE ACTIVATION OF HEDGEHOG PATHWAY AND CONSEQUENTLY THE EXPRESSION OF STEM CELL MARKERS IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA. (2014) (0)
- Report Congressuali: ASCO 2006 Gastrointestinal Cancer Symposium (2006) (0)
- P-286 Exploring chemotherapy holiday in pancreatic cancer patients responding to upfront nab-paclitaxel-gemcitabine containing regimens (2020) (0)
- 1035 THE ROLE OF VEGF AND VEGFR POLYMORPHISMS IN THE PREDICTION OF CLINICAL OUTCOME FOR ADVANCED HEPATOCELLULAR CARCINOMA RECEIVING SORAFENIB (2012) (0)
- Measurements of cellular proliferation by H-3-thymidine-labeling index and flow cytometry in breast cancer patients. (1997) (0)
- Supportive Care 1543P SYNDROME OF INAPPROPRIATE ANTI-DIURETIC HORMONE SECRETION (SIADH) IN CANCER PATIENTS (PTS): RESULTS OF THE FIRST MULTICENTER ITALIAN SURVEY (2014) (0)
- Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside (2013) (0)
- Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy. (2004) (0)
- Primary tumor histology and location as predictive factors for clinical outcome in metastatic gastric cancer (GC) patients receiving first-line chemotherapy. (2013) (0)
- p53 Status as potential predictor for response to chemotherapy in locally advanced gastric cancer (1997) (0)
- Cytokinetic effects of interferon (IFN) in colorectal tumors. Implications for the design of 5FU/IFN regimens (1993) (0)
- Should bevacizumab (B) be included in the first-line treatment of elderly patients with advanced colorectal cancer (CRC)? Results from a community-based Italian observational study. (2012) (0)
- Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241] (2022) (0)
- The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib. (2012) (0)
- General and dedicated cancer emergency room: Clinical and financial implications. (2018) (0)
- A06Patient-centred approach in a multicenter national study (E-Lung): 405 lung cancer patients and caregivers, nurses and oncologists compared (2016) (0)
- A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer (2012) (0)
- Prognostic Factors in Early Stage Non-Small Cell Lung Cancer (NSCLC): The Importance of Number of Resected Lymph Nodes and Vascular Invasion (2012) (0)
- Original Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study (2005) (0)
- Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy (2022) (0)
- Related articles (2015) (0)
- DCC and p53 protein expression in early stages of gastric cancer (1999) (0)
- Abstract P5-12-05:9Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER (2010) (0)
- [Tolerance profile of platinum compounds]. (2000) (0)
- L05eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. Final results of ePHAS study (2015) (0)
- The role of LDH serum levels in predicting global outcome in patients with HCC undergoing TACE: Implications for clinical management. (2012) (0)
- Prognostic stratification of k-RAS wild type colorectal cancer patients receiving irinotecan-cetuximab treatment: Preliminary results of a prospective study. (2013) (0)
- Antihypertensive therapy with ACE-inhibitors and clinical outcome in metastatic renal cell carcinoma (mRCC) patients. (2013) (0)
- IS5–3HER2i RESISTANCE (2013) (0)
- Tumour Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptors (VEGFR) Polymorphisms and Clinical Outcome in Advanced Renal Cell Carcinoma Patients Receiving First Line Sunitinib (2012) (0)
- Upper gastrointestinal tumours (2005) (0)
- Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery? (2014) (0)
- Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? (2018) (0)
- The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial (NCT03955393) (2020) (0)
- Focus sui tumori gastrointestinali (2006) (0)
- Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index (2023) (0)
- Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment (2012) (0)
- The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion (2022) (0)
- Multidisciplinarytreatmentof locallyadvancedrectalcancer: aliteraturereview.Part1 (2009) (0)
- The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis. (2023) (0)
- 78P Clinical outcomes with atezolizumab plus bevacizumab (AB) or lenvatinib (L) in hepatocellular carcinoma (HCC) (2022) (0)
- Clinical relevance of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome (2013) (0)
- C07Prognostic role of inflammatory markers in Mestatatic Renal Cell Carcinoma (mRCC): retrospective single-centre Italian experience (2016) (0)
- R47Secondary breast cancer prevention: it's time to get moving! (2015) (0)
- The MaiSON Project (Italy). Developing integration strategies for oncology organizations/associations through a participatory approach. (2013) (0)
- Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients (2015) (0)
- Intraperitoneal carboplatin, etoposide and interferon alpha 2b in women with residual ovarian cancer confined to peritoneum after an intravenous cisplatin containing regimen chemotherapy (1994) (0)
- The MaiSON Project (Italy). Developing Integration Strategies for Oncology Organizations/Associations through a Participatory Approach (2013) (0)
- P-151 Correlations between clinical response to cisplatin or oxaliplatin and expression of the Mismatch Repair (MMR) and p53 in advanced non-small cell lung cancer (NSCLC) patients (2003) (0)
- B02*There is a difference of vitamin D receptor gene (VDR) single-nucleotide polymorphisms (SNPs) frequencies between malignant melanoma patients and healthy volunteers and by sex? (2015) (0)
- Temporary small-gauge catheter for intraperitoneal chemotherapy : Indications and feasibility (1996) (0)
- Gender differences and outcome of melanoma patients (2015) (0)
- Colorectal Cancer With Low-dose Interferoma2b and Folinic Acid. The "GISCAD" Experience (1994) (0)
- A phase 1 study of carboplatin and α-2 interferon in patients with malignant pleural effusions (1993) (0)
- P2.04-017 Prognostic Relevance of PD-1/PD-L1 Pathway in Thymic Malignancies with Combined Immunohystochemical and Biomolecular Approach: Topic: Thymic Malignancies Clinical and Translational (2017) (0)
- Phase II study of cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (2008) (0)
- 4238 Caregivers' needs in oncology: information, information, information! (2009) (0)
- PP 23 The role of vascular endothelial growth factor (VEGF) and VEGF-receptors genotyping in guiding the metastatic process in radically resected gastric cancer patients (2011) (0)
- Abstract 2220: Impact of single-nucleotide polymorphisms (SNPs) on thymic hyperplasia and tumors outcome (2014) (0)
- Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) (2022) (0)
- A58Everolimus in ER + /HER-2 negative metastatic breast cancer (MBC): what we have learned from two years of clinical practice. A single Institution experience (2015) (0)
- The Role of Hedgehog (HH) Signaling in the Prediction of Clinical Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (0)
- D.B. Evans, P.W.T. Pisters, J.L. Abbruzzese (eds). Pancreatic Cancer (2002) (0)
- Cancer stem cells profile and clinical outcome in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy. (2014) (0)
- Chemotherapy and Radiotherapy in Pancreatic Cancer (2009) (0)
- Effect of sorafenib on cathepsin B-dependent BID-mediated apoptosis in cancer cells. (2013) (0)
- B21Mismatch repair protein expression and inflammation in human pancreatic cancer (2016) (0)
- Weekly 24-hour infusion with high-dose 5-Fluorouracil and 6s-leucovorin as a 2nd-line therapy in advanced colorectal-cancer resistant to a 5-fluorouracil/6s-leucovorin bolus combination. (1995) (0)
- Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (2020) (0)
- Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study. (2019) (0)
- A randomised phase II study of cetuximab plus gemcitabine/cisplatin combination in advanced pancreatic cancer (APC) (2007) (0)
- [Adjuvant therapy of colon cancer. State of the art and future perspectives]. (1999) (0)
- C07Soft tissue sarcoma after haematological malignancies in childhood/adolescence: a hospital series (2015) (0)
- A novel clinical-pathological score correlates with global outcome of locally advanced rectal cancer patients receiving neoadjuvant chemo-radiotherapy (2005) (0)
- Correction: Liberati, S., et al. Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression. Cells 2014, 3, 112–128 (2014) (0)
- MA 11.11 Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients (2017) (0)
- Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? (2021) (0)
- c-erbB-2 and common prognostic factors in breast cancer patients. (1996) (0)
- B07An Italian Cost-Effectiveness Analysis of Paclitaxel Albumin (nab®-paclitaxel) + Gemcitabine vs Gemcibatine alone for Metastatic Pancreatic Cancer Patients: The APICE Study (2016) (0)
- R03Prognostic factors in glioblastoma patients treated with the nitrosourea fotemustine at first relapse after the Stupp regimen: results from the GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology) (2015) (0)
- D21 Prediction of overall survival after 3 months of treatment using the NLR-over-the-time curve in pancreatic cancer patients (2017) (0)
- Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . (2018) (0)
- MO-0880 Quantifying individual dose relationships for pCR in rectal cancer: potentials for a customized dose (2022) (0)
- Immune Inflammation Indicators Predict Outcome in Anal Cancer Patients Undergoing Concurrent Chemoradiation (2018) (0)
- 737PANGIOGENESIS POLYMORPHISMS PROFILE IN THE PREDICTION OF CLINICAL OUTCOME OF ADVANCED HCC PATIENTS RECEIVING SORAFENIB: COMBINED ANALYSIS OF VEGF AND HIF-1. THE ALICE-2 STUDY. (2014) (0)
- SAT-456-New multi inflammation indicators in advanced hepatocellular carcinoma patients receiving sorafenib (2019) (0)
- Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. (2015) (0)
- P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. (2018) (0)
- Tumor cancer stem cell genetic profile as predictor of relapse in stage II and III radically resected colon cancer patients. (2013) (0)
- 105P Thoracic radiotherapy and tyrosine kinase inhibitors association: Results from a monoinstitutional experience (2023) (0)
- Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT. (2016) (0)
- F55Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience (2016) (0)
- Advanced gastric cancer: is there an optimal chemotherapy regimen? (2017) (0)
- Over D1 lymph-nodes dissection may question the value of post-operative radiotherapy as a part of an adjuvant program in radically resected gastric cancer patients. (2004) (0)
- H50Clinical and pathological predictors of outcome for malignant pleural mesothelioma (2015) (0)
- Adjuvant therapies in patients with colorectal cancer: An audit on clinical practice in Italy (2004) (0)
- First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiAlLdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis. (2016) (0)
- Correlation of allele polymorphisms of tumor integrins with peritoneal carcinosis capability of gastric cancer cells in radically resected patients (2010) (0)
- D04Evaluation of clinical and pathological features in patients with Lynch Syndrome-related Endometrial Cancer: a single centre experience (2015) (0)
- BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience. (2019) (0)
- STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY (2016) (0)
- Tumor angiogenesis as predictive factor for site of relapse in patients with gastric cancer: Biological and clinical implications. (2011) (0)
- N02Mindfulness-based Stress Reduction (MBSR) in cancer patients: prospective single-centre case-control study (MIND4ME study) (2016) (0)
- 1104PIncidence and survival of secondary malignances (SM) in oropharingeal squamous cell carcinoma (OPSCC): A homogeneous single report institution (2017) (0)
- 8743 POSTER Efficacy of Fotemustine in Recurrent Malignant Glioma According to Time to Adjuvant Temozolomide Failure – a Pooled Analysis (2011) (0)
- OC-13 The role of VEGF and VEGFR polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib (2012) (0)
- Family history of pancreatic cancer in BRCA1/2 testing criteria. (2017) (0)
- VEGF and VEGFRs polymorphisms analysis in advanced renal cell carcinoma tissues: Is heterogeneity ever the answer? (2014) (0)
- Neuroprotective E ffect o f R educed G lutathione o n Oxaliplatin-Base d C hemotherapy i n A dvanced Colorectal C ancer: A R andomized, D ouble-Blind, Placebo-Controll ed T rial (2007) (0)
- High neutrophil to lymphocyte ratio persistent during first-line chemotherapy to predict clinical outcome in patients with advanced urothelial cancer. (2014) (0)
- M07BRAF, NRAS and C-KIT mutations segregate distinct clinical and histopathological profiles in patients with melanoma (2016) (0)
- [354] THE SELECTIVE INHIBITION OF THE NA+/H+ EXCHANGER BY CARIPORIDE INCREASES THE ANTINEOPLASTIC EFFECT OF GEMCITABINE IN HUMAN CHOLANGIOCARCINOMA CELLS THROUGH MODULATION OF PHARMACORESISTANCE (2007) (0)
- Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma (2022) (0)
- From biology to treatment in advanced pancreatic and gastroesophageal cancer (2012) (0)
- Efficacy and toxicity of a low dose regimen of capecitabine and oral vinorelbine (2008) (0)
- Professional failure: how do oncologists feel it? (2011) (0)
- Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: Lessons from clinical practice (2011) (0)
- Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. (2023) (0)
- 1479P Exploring second-line therapy outcome in pancreatic ductal adenocarcinoma (PDAC) patients with germlineBRCA1-2 pathogenic variants (gBRCA1-2pv) (2021) (0)
- ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. (2018) (0)
- Bone metastases- Pharmacological treatment (2010) (0)
- Potential Clinical Application and Trials (2012) (0)
- Prognostic Significance of EGFR, HER-2, CEA on Circulatingtumour Cells (CTCS) in Patients with Metastatic Non-Small-Cell Lung Cancer (MNSCLC) (2012) (0)
- 1543PSYNDROME OF INAPPROPRIATE ANTI-DIURETIC HORMONE SECRETION (SIADH) IN CANCER PATIENTS (PTS): RESULTS OF THE FIRST MULTICENTER ITALIAN SURVEY. (2014) (0)
- Prognostic and predictive value of hedgehog (Hh) signaling in advanced non-small cell lung cancer (NSCLC). (2012) (0)
- Oxaliplatin (L-OHP) in combination with leucovorin and bolus-continuous infusion 5fluorouracil (LV5FU2) in advanced colorectal cancer (ACC) pretreated with 5fu (1999) (0)
- 111P Identification of atezolizumab plus bevacizumab prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma: The ABE index (2022) (0)
- Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials (2019) (0)
- Quality of life and anxious-depressive symptoms in cancer patients undergoing mindfulness-based interventions: Feasibility and preliminary outcomes on prospective single-centre case-control study (MIND4MESt.) (2017) (0)
- 65P Prognostic role of PECS2 index in advanced biliary tract cancer (BTC) patients treated with first line chemotherapy: Training and validation cohorts (2020) (0)
- clinical practice guidelines Pancreatic cancer : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow-up (2010) (0)
- Osteopontin (OPN) and interleukin-6 (IL-6) as predictive biomarkers in HCC receiving loco-regional treatment: Preliminary results (2015) (0)
- P3500Atrial fibrillation in active malignancy: prescription of anticoagulants and impact on all-cause mortality (2018) (0)
- The presence of bone (BM) and concomitant non-bone metastases (cNBM) significantly worsens the 2-year overall survival (OS) in breast cancer (BC) patients (PTS): Update of results in the moon study (2005) (0)
- 342PBASELINE NEUTROPHIL TO LYMPHOCYTE RATIO CORRELATES WITH TUMOR STAGE IN LOCALLY ADVANCED BREAST CANCER PATIENTS. (2014) (0)
- B13Clinical and pathological features of rare histological exocrine pancreatic cancers (PCs): a retrospective multicentric analysis (2016) (0)
- A Meta-Analysis of Clinical Trials on the Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies (2015) (0)
- New drugs and pharmacology /Palliative and supportive care (2005) (0)
- Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab (2012) (0)
- OC.07.6 DIET AND LIFESTYLE HABITS IN EARLY-ONSET COLORECTAL CANCER: A PILOT CASE CONTROL STUDY (2021) (0)
- Abstract 12440: Global Longitudinal Strain With 2D-Speckle Tracking Predicts Chemotherapy-related Systolic Dysfunction Independenty of Basal Assessment in Patients With Breast Carcinoma (2015) (0)
- F17Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis (2015) (0)
- Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab (2015) (0)
- The prognostic nutritional index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L) (2019) (0)
- The role of primary tumour location in the recurrence rate of metachronous metastasis of colon cancer. (2018) (0)
- Targeting Hedgehog in pancreatic cancer: An innovative approach but not for all tumors. (2013) (0)
- Treatment of metastatic renal cell carcinoma with daily high dose of alpha 2b interferon. A phase II study (1991) (0)
- [ASCO 2006 Annual Meeting, Atlanta, June 2-6, 2006. Focus on gastrointestinal tumors]. (2006) (0)
- Epidermal growth factor receptor (EGFR) status in different stages of resected non-small cell lung cancer (NSCLC): Implications for treatment with EGFR-targeted monoclonal antibodies. (2006) (0)
- LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first-line chemotherapy. (2015) (0)
- Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study (2016) (0)
- Molecular selection for colorectal cancer (CRC) patients receiving cetuximab: Final results of a prospective study. (2015) (0)
- PR20 Biology of BRCA-related triple-negative breast cancer: which is the difference with the others? (2014) (0)
- Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors FRANCESCOPANZUTO, a MARIARINZIVILLO, a NICOLAFAZIO, b FILIPPODEBRAUD, c GABRIELELUPPI, d MARIACHIARAZATELLI, e FRANCESCALUGLI, f (2014) (0)
- The prognostic impact of sidedness across all stages during the last 20 years: the "Modena Cancer Registry" experience. (2017) (0)
- Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice. (2014) (0)
- Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). (2016) (0)
- A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index (2021) (0)
- The genomic landscape of IDH1 mutant intrahepatic cholangiocarcinoma: a multicentre comprehensive analysis (2022) (0)
- Beta 4 Integrin Polymorphism Mediate an Alternative Resistance Pathway in HER-3 Negative, K-RAS Wild Type Metastatic Colorectal Patients Receiving Irinotecan Cetuximab (2012) (0)
- PO-1225 Hypofractionated radiotherapy after induction chemotherapy for advanced pancreatic cancer (2021) (0)
- 752PPROGNOSIS OF BRCA1 AND BRCA2-RELATED BREAST CANCERS: ARE THERE DIFFERENCES? (2014) (0)
- Adjuvant therapies in patients with colorectal cancer: An audit on clinical practice in Italy. (2004) (0)
- The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for patients with advanced renal cell carcinoma receiving first-line sunitinib. (2012) (0)
- The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for patients with advanced renal cell carcinoma receiving first-line sunitinib. (2012) (0)
- HER2 expression in patients with advanced pancreatic cancer: Preliminary results from a multifactorial biologic analysis. (2012) (0)
- L04Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: combined analysis of VEGF and HIF-1a. Final results of the ALICE-2 study (2015) (0)
- A novel electronic tool to implement palliative sedation (PS) in a department of oncologic medicine. (2018) (0)
- Radial and Longitudinal Margins in Surgery of Perihilar Cholangiocarcinoma: When R1 Definition is Associated with Different Prognosis (2021) (0)
- Subject Index Vol. 71, 2006 (2007) (0)
- Atezolizumab and bevacizumab in advanced HCC: ready for prime time? (2020) (0)
- OTT_A_192572 2981..2988 (2019) (0)
- Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience (2021) (0)
- [Evolution of the parameters indicating response to drug therapy: from regression to complete control of the disease and the symptoms]. (2002) (0)
- melanoma & skin cancer M09 Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer (2016) (0)
- Correlation between VEGF and VEGF-R polymorphisms, toxicity, and clinical outcome in HCC patients receiving sorafenib. (2013) (0)
- Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. (2017) (0)
- Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study (2020) (0)
- Physical exercise guidelines in oncology. (2013) (0)
- Notch Activation Modulates Bevacizumab Activity by CD44 Positive Cancer Stem Cells in Advanced Colon Cancer (2017) (0)
- H19Impact and prognostic role of single-neucleotide polymorphisms (SNPs) in thymic lesions (2015) (0)
- FOLFIRNOX for advanced pancreatic cancer (aPDAC) according to schedule and dose modifications: Clinical feasibility and impact of supportive care. (2015) (0)
- Influence of 5-Fluorouracil and Folinic Acid on Interleukin-18 Production in Colorectal Cancer Patients (2002) (0)
- 703PWHO SHOULD RECEIVE FIRST-LINE FOLFIRINOX? PROGNOSTIC FACTORS IN LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER PATIENTS. (2014) (0)
- Contents Vol. 71, 2006 (2007) (0)
- A38BRCA1/2 mutations and hereditary breast cancer: clinical phenotype, type of mutation and founder effect (2015) (0)
- Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer (2012) (0)
- L01*Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD) (2015) (0)
- [Colonic cancer. Adjuvant therapy: the Italian experience]. (2001) (0)
- ERBB2 and PI3KCA mutations in endocrine resistant breast cancer (BC). (2018) (0)
- The role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome. (2018) (0)
- E42Role of different toxicity profile on outcome for colorectal cancer patients receiving Regorafenib monotherapy (2015) (0)
- D17Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial (2016) (0)
- 2390 LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy (2015) (0)
- THU-448-Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study (2019) (0)
- Correlation between everolimus discontinuation or dose reduction induced by stomatitis or cutaneous toxicity and clinical outcome in patients with metastatic renal cell carcinoma. (2015) (0)
- Nuclear factor kB (NF-kB) may predict efficacy of cetuximab therapy in EGFR-positive colorectal cancer (2007) (0)
- 3092 Systemic immune-inflammation index (SII) in patients with advanced non-small cell lung cancer (nsclc) (2015) (0)
- R12Risk for developing hyponatraemia in cancer patients treated with targeted therapies: a meta-analysis (2015) (0)
- 2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study (2015) (0)
- Pre-operative treatment modalities in gastric cancer patients. (2005) (0)
- The Role of Tumour Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptors (VEGFR) Polymorphisms in the Prediction of Clinical Outcome for advanced Hepatocellular Carcinoma Receiving Sorafenib (2012) (0)
- F14Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs) (2015) (0)
- 706PHER FAMILY RECEPTOR EXPRESSION AND CLINICAL OUTCOME IN PANCREATIC CANCER PATIENTS. (2014) (0)
- 72MO Clinical outcomes and response (R) with atezolizumab plus bevacizumab (AB) or lenvatinib (L) in hepatocellular carcinoma (HCC) (2022) (0)
- A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (ABTC) receiving first-line chemotherapy (1-line cht). (2018) (0)
- [Some aspects to discuss in the care of the elderly oncologic patient]. (2004) (0)
- Correlation of tumor integrins and peritoneal carcinosis capability of gastric cancer. (2010) (0)
- Role of docetaxel in the treatment of advanced gastric carcinoma (2009) (0)
- Angiogenic profile and pathological features in the prediction of clinical outcome of advanced renal cell carcinoma patients receiving sunitinib. (2015) (0)
- Correlation of stomatitis and cutaneous toxicity with clinical outcome in patients with metastatic renal cell carcinoma treated with everolimus. (2013) (0)
- Validation and refinement of PROSASH model using the neutrophil‐to‐lymphocyte ratio in patients with HCC receiving sorafenib (2020) (0)
- Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . (2018) (0)
- L09Mismatch repair protein expression and Hedgehog signalling pathways in human pancreatic cancer (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stefano Cascinu?
Stefano Cascinu is affiliated with the following schools:
